many resections with no cancer in the specimen (11 vs. 3 per 100 person years; p<0.001, Figure) . Progression to invasive disease was uncommon, and frequent cystoscopy was associated with shorter time to progression (5% at 1.0 year vs. at 2.3 years; p[0.005). Bladder cancer death was rare and not associated with frequent cystoscopy (3% at 5.4 years vs. at 5.3 years, p[0.820). On sensitivity analyses assuming all patients had intermediate risk disease, 469 patients (45%) had more frequent cystoscopy than recommended (>5 cystoscopies in the first 2 years), and associations between frequent cystoscopy and outcomes remained unchanged.
INTRODUCTION AND OBJECTIVES:
Hematuria is prevalent, with over 2 million US patients referred to urologists annually. Historical U.S. guidelines recommend CT for all adults with any degree of hematuria, whereas international guidelines recommend ultrasound, explicitly citing concerns about cost effectiveness and radiation harms. Against this backdrop, physicians in Kaiser Permanente (KP) developed a new risk-stratified guideline for hematuria, with CT restricted to patients at highest risk [gross hematuria (GH)], renal ultrasound for patients with microhematuria and risk factors [(MHRF) tobacco exposure, men, women >50 years old)] and no evaluation for nonsmoking women <50 years old with low-risk microhematuria (LRMH).
METHODS: 156,926 patients with hematuria in three health systems from 2010-2016 were identified. Two systems [KP Northern California (KPNC) and KP Northwest (KPNW)] adopted the new riskstratified guideline in 2012-2013; the third system, KP Washington (KPWA), did not adopt any specific guideline during this period. We compared trends in CT utilization within and between systems among the three risk groups before (2010-11) and after (2014-15) guideline adoption.
RESULTS: Among patients with an episode of care for hematuria evaluation (n[81,291) , the system with highest baseline CT utilization (KPNC) had stable utilization of CT for GH patients (74.7% to 73.8%, p[.2301) and substantial decreases in CT utilization for MHRF (67.6% to 44.5%, p<.0001) and LRMH (52.1% to 43.8%, p<.0001) patients after adoption of the new guideline. The system with lowest baseline CT utilization (KPNW) had guideline-concordant increase in CT utilization for GH patients (22.0% to 68.3%, p<.0001), but also modest guideline-discordant increase in CT for MHRF ( CONCLUSIONS: Adoption of a risk-stratified guideline was associated with differential changes in utilization within and across health systems, sensitive to baseline CT utilization and patient risk factors. Substantial residual variation in utilization suggests additional opportunities for improvement.
Source of Funding: Kaiser Permanente Patient Outcomes Research to Advance Learning (PORTAL) Pilot Award

PD67-12 BENEFIT OF EARLY TREATMENT WITH BONE-MODIFYING AGENTS FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH GENITOURINARY CANCER WITH BONE METASTASIS: A LARGE SCALE MULTI-INSTITUTIONAL STUDY
Takuya Owari*, Makito Miyake, Yoshitaka Itami, Kenta Onishi, Nobumichi Tanaka, Kiyohide Fujimoto, Kashihara-shi, Japan INTRODUCTION AND OBJECTIVES: Skeletal-related events (SREs) induced by bone metastasis (BM) can result in reduced QOL, and increased in healthcare burdens. This multi-institutional retrospective study aimed to evaluate the clinical benefit of bonemodifying agents (BMAs), zoledronic acid and denosumab, and identify risk factors of SREs in patients with genitourinary cancer with BM.
METHODS: The study participants included a total of 650 patients with BM of the following cancer types: hormone-sensitive prostate cancer (HSPC; n [ 443), castration-resistant prostate cancer (CRPC; n [ 50), renal cell carcinoma (RCC; n [ 80), and urothelial carcinoma (UC; n [ 77) . Clinical factors at the time of diagnosis of bone metastasis were analyzed. SREs were defined as pathological fracture, spinal cord compression, or the need for palliative radiotherapy/surgery for BM lesions. Early treatment with BMAs was defined as follows: administration of BMAs before the development of SREs and within 6 months from the diagnosis of BM. Vol. 201, No. 4S, Supplement, Monday, May 6, 2019 THE JOURNAL OF UROLOGY Ò e1203
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